Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...
Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.